Dr. Cohen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E., LG465
Seattle, WA 98109Phone+1 206-606-6658
Summary
- Stacey Cohen, MD is a Gastrointestinal Medical Oncology specialist based in Seattle, WA. Dr. Cohen obtained her medical degree from the University of Michigan Medical School and completed her Internal Medicine residency there as well. She completed her Hematology/Oncology fellowship at the University of Washington/Fred Hutchinson Cancer Center. Besides her clinical practice, her experience includes conducting clinical and translational research and circulating tumor DNA (ctDNA). She has published her research in respected journals such as Nature, Gastroenterology, Epigenetics, Journal of the National Comprehensive Cancer Network, and Supportive Care in Cancer.
Education & Training
University of WashingtonFellowship, Medical Oncology, 2014
University of MichiganResidency, Internal Medicine, 2008 - 2011
University of Michigan Medical SchoolClass of 2008
Certifications & Licensure
MT State Medical License 2022 - 2027
WA State Medical License 2011 - 2025
MI State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Alcohol Consumption and Smoking History at the Time of Diagnosis and the Risk of Colorectal Cancer Recurrence and Mortality: Results from the ColoCare Study.Nicole C Loroña, Caroline Himbert, Jennifer Ose, Stacey A Cohen, Ildiko Strehli
Cancer Epidemiology, Biomarkers & Prevention. 2025-01-09 - Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients.Ronan W Hsieh, Lynn K Symonds, Jason Siu, Stacey A Cohen
International Review of Cell and Molecular Biology. 2025-01-01 - 3 citationsEvaluating the utility ofpromoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance).Elizabeth S Nakasone, Tyler J Zemla, Ming Yu, She Yu Lin, Fang-Shu Ou
Epigenetics. 2024-12-01
Press Mentions
ctDNA Analysis Not Enough to Guide Treatment Decisions in Early Pancreatic CancerJune 4th, 2024- Peripheral Neuropathy: When Having No Pain Is a Big ProblemMarch 27th, 2023
- Some Cancer Patients May Not Need Treatments After SurgeryJune 14th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
